Endotracheal Surfactant and Budesonide Combination Therapy in Neonatal Acute Respiratory Distress Syndrome due to Late-Onset Sepsis
- PMID: 39492564
- PMCID: PMC11532653
- DOI: 10.34172/aim.31725
Endotracheal Surfactant and Budesonide Combination Therapy in Neonatal Acute Respiratory Distress Syndrome due to Late-Onset Sepsis
Abstract
Background: Neonatal acute respiratory distress syndrome (NARDS) is an important cause of hypoxemic respiratory failure. This study aimed to investigate the short-term effects of endotracheal surfactant and budesonide combination therapy on NARDS secondary to late-onset neonatal sepsis (LONS).
Methods: This was a retrospective, cross-sectional, and observational study. Newborns with NARDS due to LONS who received endotracheal surfactant and budesonide combination therapy between August 2022 and September 2023 were included in this study. Oxygenation status before endotracheal surfactant and budesonide treatment were compared with the values obtained two hours after treatment.
Results: Among 20 neonates, 10 (50%) were diagnosed with severe NARDS, and 10 (50%) were diagnosed with moderate NARDS. The mean corrected gestational age was 33.3±2.9 w when endotracheal surfactant and budesonide were administered to the neonates. The need for the fraction of inspired oxygen (0.75 [0.57-1.00]% vs. 0.55 [0.44-0.80]%; mean difference [MD]: 17.50%, 95% confidence interval [CI]: 14.99 to 22.50) and oxygen saturation index (OSI; 8.03 [4.98-13.94] vs. 4.71 [4.11-8.93]; MD: 2.23, 95% CI: 1.22 to 3.24) decreased (P=0.001 and P<0.001, respectively) after endotracheal surfactant and budesonide treatment. However, preductal oxygen saturation (SpO2 ; 93 [91-94]% vs. 95 [94-96]%; MD: -3.50%, 95% CI: -5.00 to -2.00) increased significantly after endotracheal surfactant and budesonide treatment when compared to pre-treatment values (P<0.001).
Conclusion: The reduction in oxygen demand and OSI, along with an increase in SpO2 after treatment compared to pre-treatment values, suggests that endotracheal surfactant and budesonide combination therapy could be an effective option to improve oxygenation in NARDS secondary to LONS.
Keywords: Acute respiratory distress syndrome; Budesonide; Endotracheal therapy; Neonates; Surfactant.
© 2024 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflict of interest statement
The authors declare that they have no conflict of interests.
Similar articles
-
Bovine surfactant in the treatment of pneumonia-induced-neonatal acute respiratory distress syndrome (NARDS) in neonates beyond 34 weeks of gestation: a multicentre, randomized, assessor-blinded, placebo-controlled trial.Eur J Pediatr. 2021 Apr;180(4):1107-1115. doi: 10.1007/s00431-020-03821-2. Epub 2020 Oct 21. Eur J Pediatr. 2021. PMID: 33084980 Free PMC article. Clinical Trial.
-
Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia.Am J Respir Crit Care Med. 2016 Jan 1;193(1):86-95. doi: 10.1164/rccm.201505-0861OC. Am J Respir Crit Care Med. 2016. PMID: 26351971 Clinical Trial.
-
Risk Factors of Neonatal Acute Respiratory Distress Syndrome Based on the Montreux Definition in Neonates with Sepsis: A Retrospective Case-Control Study.Am J Perinatol. 2024 Jun;41(8):1019-1026. doi: 10.1055/a-1788-5121. Epub 2022 Mar 4. Am J Perinatol. 2024. PMID: 35253119
-
Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.Neonatology. 2015;107(4):358-9. doi: 10.1159/000381132. Epub 2015 Jun 5. Neonatology. 2015. PMID: 26044104 Review.
-
Surfactant therapy for respiratory distress syndrome in premature neonates: a comparative review.Am J Respir Med. 2002;1(6):417-33. doi: 10.1007/BF03257169. Am J Respir Med. 2002. PMID: 14720029 Review.
Cited by
-
A nomogram for predicting neonatal acute respiratory distress syndrome in patients with neonatal pneumonia after 34 weeks of gestation.Front Pediatr. 2025 Jan 9;12:1451466. doi: 10.3389/fped.2024.1451466. eCollection 2024. Front Pediatr. 2025. PMID: 39850203 Free PMC article.
-
Comparative Efficacy and Safety Profile of the Combination of Pulmonary Surfactant and Budesonide vs. Surfactant Alone in the Management of Neonatal Respiratory Distress Syndrome: An Updated Meta-Analysis.Medicina (Kaunas). 2025 Jul 23;61(8):1329. doi: 10.3390/medicina61081329. Medicina (Kaunas). 2025. PMID: 40870374 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources